Icon PLC

ICLR

Equity

ISIN IE0005711209 / Valor 1017575

NASDAQ (2025-11-21)

USD 164.56+4.07%

Icon PLC
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

ICON plc is a leading global provider of outsourced drug and medical device development and commercialization services, catering to pharmaceutical, biotechnology, and medical device companies as well as government and public health organizations. The company specializes in managing the entire product lifecycle, including the planning, execution, and analysis of Phase I-IV clinical trials, which range from small single-site studies to large, multinational projects and advancements in cell and gene therapy. ICON also offers Functional Service Provision (FSP), delivering essential support services in areas such as finance, IT, human resources, sales, quality assurance, facilities, administration, legal, and procurement. With over 13,000 employees and more than 90 global partnerships, ICON integrates its Strategic Solutions teams within clients' operations to enhance efficiency and accelerate the market entry of new therapeutics and devices. Additionally, ICON is committed to developing talent through various early career programs, fostering a culture of continuous learning and professional growth.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue & Profitability

ICON PLC’s revenue reached $2,042.8 million in Q3 2025, representing a slight increase of 1.3% from Q2 2025. GAAP net income for the quarter was $2.4 million ($0.03 per diluted share), while adjusted net income stood at $258.8 million ($3.31 per diluted share), underscoring improved operating performance despite the impact of a $165.3 million non-cash goodwill impairment within the Data Solutions Reporting Unit.

EBITDA & Cash Flow

Adjusted EBITDA for Q3 2025 was $396.7 million, constituting 19.4% of revenue. Additionally, operational cash generation was strong, with free cash flow reported at $333.9 million during the quarter, highlighting the company’s effective cash conversion and disciplined capital expenditure management.

Business Wins & Order Intake

Q3 2025 saw robust business momentum with $2,986 million in gross business wins and $2,086 million in net business wins, delivering a healthy book-to-bill ratio of 1.02. These figures reflect ICON PLC’s continued success in securing new contracts amid ongoing market challenges.

Capital Management & Guidance

ICON PLC maintained a net debt level of $2.9 billion and repurchased approximately $250.0 million of stock during Q3 2025. The company also updated its full-year 2025 revenue guidance to a range of $8,050–$8,100 million and adjusted diluted earnings per share guidance to $13.00–$13.20, reflecting adjustments for the evolving market environment.

Summarized from source with an LLMView Source

Key figures

-22.7%1Y

-23.9%3Y

-13.2%5Y

Performance

45.7%1Y

38.4%3Y

37.4%5Y

Volatility